Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
FOLD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.51 - $12.65
Previous CloseN/A
Volume320.41K
Average Volume (3M)4.48M
Market Cap
$2.64B
Enterprise Value$1.98B
Total Cash (Recent Filing)$231.00M
Total Debt (Recent Filing)$443.31M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Nov 05, 2025EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding308,239,380
10 Day Avg. Volume5,529,822
30 Day Avg. Volume4,476,558
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue3.46
Enterprise Value/Gross Profit3.83
Enterprise Value/Ebitda59.84
Forecast
1Y Price Target
$15.86Price Target Upside89.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Intellectual PropertyThe US District Court for the District of Delaware has denied Aurobindo’s motion for summary judgement of patent ineligibility, supporting franchise durability.
Pipeline ExpansionFOLD announced new future US PomOp manufacturing and in-licensed Ph3 DMX-200 in FSGS, indicating pipeline expansion.
Regulatory ApprovalReduction in proteinuria is a suitable primary endpoint for full approval in FSGS, lowering regulatory risk for DMX-200.
Bears Say
Financial GuidanceFY25 non-GAAP operating expenses guidance increased due to a $30M upfront licensing payment.
Legal ChallengesThe trial will likely include invalidity challenges on grounds other than Section 101.
Revenue And ExpensesFY25 total revenue guidance was lowered due to an unexpectedly higher UK VPAG rebate rate.
Amicus News
FOLD FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $5.51 and its highest was $12.65 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Amicus Therapeutics’s market cap is $2.64B.
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 40 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Jul 31, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.118 by $0.038.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is 0.04.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 308,239,380 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.118. Following the earnings report the stock price went down -2.284%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Currently, no hedge funds are holding shares in FOLD
Amicus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.86 (89.94% Upside)
$15.86 (89.94% Upside)
Blogger Sentiment
Bullish
FOLD Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 12.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.57%
12-Months-Change
Fundamentals
Return on Equity
-22.62%
Trailing 12-Months
Asset Growth
8.78%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
FOLD Company Deck
FOLD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong quarter for Amicus Therapeutics with significant revenue growth and strategic advancements, particularly in Galafold and Pombiliti/Opfolda sales. Despite increased operating expenses and a decline in non-GAAP net income, the company's positive revenue trajectory, successful product launches, and advancements in their strategic partnership with Dimerix for DMX-200 highlight a positive outlook.View all FOLD earnings summariesFOLD Stock 12 Month Forecast
Average Price Target
$15.86
▲(89.94% Upside)
Technical Analysis
Catalyst Pharma
―
Travere Therapeutics
―
Ocular Therapeutix
―
Immunovant
―
Disc Medicine
―
Ownership Overview
1.16% Insiders
30.33% Mutual Funds
34.49% Other Institutional Investors
16.20% Public Companies and
Individual Investors